Ali Mortazavi, Chief Executive Officer of Silence Therapeutics LON:SLN commented: “The grant of US 9,695,423 is further confirmation by the US Patent Office of the validity of our patent claims that
Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that its
Silence Therapeutics plc (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, notes Alnylam Pharmaceutical’s press release
Silence Therapeutics plc, LON:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need,
Silence Therapeutics plc (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today the hiring of
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented: “These granted patents and patent applications within the US and Europe are key to our leading IP position in the RNAi
Silence Therapeutics plc, LON:SLN (“Silence” or “the Company”) a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need,
Silence Therapeutics plc LON:SLN Chief Executive Officer Ali Mortazavi commented: “2016 was a year of transformation and transition for RNAi and Silence. The field has moved on rapidly based on
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics LON:SLN, commented: “We believe that the recent technological advancements in RNA therapeutics have been underestimated and undervalued. We are confident that the recent
Silence Therapeutics’ Ali Mortazavi discusses in vivo CRISPR/Cas9 gene editing data in this exclusive interview with DirectorsTalk
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
